Clinical-stage regenerative medicine company Regeneus Ltd (ASX: RGS) has received notification from the Japanese Patent Office that it will grant the company a new key patent, covering the use of its lead stem cell technology Progenza to treat pain, through to 2032.
Regeneus already holds granted patents for the use of Progenza to treat inflammatory conditions, such as osteoarthritis. This new patent expands Regeneus’ intellectual property portfolio into the $85.5 billion global pain market.
Pursuant to the terms of the company’s licence and collaboration agreement with Kyocera Corporation, to commercialise Progenza OA in Japan, Kyocera also has first rights to develop Progenza for additional indications for the Japanese market. The patent to be granted covering the use of Progenza to treat pain is included within this agreement.
Regeneus CEO, Karolis Rosickas, said the patent supports the company’s plan to explore additional licences for Progenza to treat other indications.
Regeneus continues to explore all opportunities to address the gap in the projected $85.5B global pain management drugs market with our disease modifying stem cell technologies,” Mr Rosickas said.
“This new key patent will support the company’s efforts by helping us secure new licences for Progenza to treat other indications relating to pain.”